Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine
- Development stage
- Phase 1
- Lead developer
- Mayo Clinic
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
Malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine is a cell-based vaccine therapy designed to treat glioblastoma. It involves taking a patient's own dendritic cells, which are a type of immune cell, and 'pulsing' them with proteins (lysate) derived from allogeneic malignant glioma tumors. These pulsed dendritic cells are then administered back to the patient to present tumor-associated antigens to the immune system, aiming to stimulate a specific and effective immune response to kill glioblastoma tumor cells. It has been investigated in clinical trials for both recurrent and newly diagnosed glioblastoma.
- Other names
- autologous dendritic cell / allogeneic glioblastoma multiforme culture lysate vaccinationallogeneic tumor primary tumor culture lysate / autologous dendritic cell (DC) vaccination
Beyond the preview
Go deeper on malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine.